141 related articles for article (PubMed ID: 15995324)
1. Systemic mastocytosis: bone marrow pathology, classification, and current therapies.
Pardanani A
Acta Haematol; 2005; 114(1):41-51. PubMed ID: 15995324
[TBL] [Abstract][Full Text] [Related]
2. Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib.
Florian S; Esterbauer H; Binder T; Müllauer L; Haas OA; Sperr WR; Sillaber C; Valent P
Leuk Res; 2006 Sep; 30(9):1201-5. PubMed ID: 16406018
[TBL] [Abstract][Full Text] [Related]
3. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial.
Droogendijk HJ; Kluin-Nelemans HJ; van Doormaal JJ; Oranje AP; van de Loosdrecht AA; van Daele PL
Cancer; 2006 Jul; 107(2):345-51. PubMed ID: 16779792
[TBL] [Abstract][Full Text] [Related]
4. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness.
Klion AD; Noel P; Akin C; Law MA; Gilliland DG; Cools J; Metcalfe DD; Nutman TB
Blood; 2003 Jun; 101(12):4660-6. PubMed ID: 12676775
[TBL] [Abstract][Full Text] [Related]
5. Modern diagnosis and treatment of primary eosinophilia.
Tefferi A
Acta Haematol; 2005; 114(1):52-60. PubMed ID: 15995325
[TBL] [Abstract][Full Text] [Related]
6. Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management.
Pardanani A
Am J Hematol; 2015 Mar; 90(3):250-62. PubMed ID: 25688753
[TBL] [Abstract][Full Text] [Related]
7. Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis.
Bain BJ
Am J Hematol; 2004 Sep; 77(1):82-5. PubMed ID: 15307112
[TBL] [Abstract][Full Text] [Related]
8. Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management.
Pardanani A
Am J Hematol; 2013 Jul; 88(7):612-24. PubMed ID: 23720340
[TBL] [Abstract][Full Text] [Related]
9. [Systemic mastocytosis].
Fain O; Stirnemann J; Eclache V; Barete S; Casassus P; Hermine O; Lorholary O
Presse Med; 2005 May; 34(9):681-7. PubMed ID: 15988348
[TBL] [Abstract][Full Text] [Related]
10. Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management.
Pardanani A
Am J Hematol; 2011 Apr; 86(4):362-71. PubMed ID: 21442641
[TBL] [Abstract][Full Text] [Related]
11. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia.
Pardanani A; Brockman SR; Paternoster SF; Flynn HC; Ketterling RP; Lasho TL; Ho CL; Li CY; Dewald GW; Tefferi A
Blood; 2004 Nov; 104(10):3038-45. PubMed ID: 15284118
[TBL] [Abstract][Full Text] [Related]
12. Eosinophilia in mast cell disease.
Kovalszki A; Weller PF
Immunol Allergy Clin North Am; 2014 May; 34(2):357-64. PubMed ID: 24745679
[TBL] [Abstract][Full Text] [Related]
13. Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias.
Vandenberghe P; Wlodarska I; Michaux L; Zachée P; Boogaerts M; Vanstraelen D; Herregods MC; Van Hoof A; Selleslag D; Roufosse F; Maerevoet M; Verhoef G; Cools J; Gilliland DG; Hagemeijer A; Marynen P
Leukemia; 2004 Apr; 18(4):734-42. PubMed ID: 14973504
[TBL] [Abstract][Full Text] [Related]
14. Mastocytosis: state of the art.
Horny HP; Sotlar K; Valent P
Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883
[TBL] [Abstract][Full Text] [Related]
15. Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management.
Pardanani A
Am J Hematol; 2019 Mar; 94(3):363-377. PubMed ID: 30536695
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment of KIT D816V-positive, imatinib-resistant systemic mastocytosis with interferon-alpha.
Yoshida C; Takeuchi M; Tsuchiyama J; Sadahira Y
Intern Med; 2009; 48(22):1973-8. PubMed ID: 19915299
[TBL] [Abstract][Full Text] [Related]
17. Charcot-Leyden crystals in the trephine biopsy of a patient with a FIP1L1-PDGFRA - positive myeloproliferative disorder.
Lyall H; O'Connor S; Clark D
Br J Haematol; 2007 Aug; 138(4):405. PubMed ID: 17593250
[No Abstract] [Full Text] [Related]
18. Systemic mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management.
Pardanani A
Am J Hematol; 2012 Apr; 87(4):401-11. PubMed ID: 22410759
[TBL] [Abstract][Full Text] [Related]
19. Morphologically occult systemic mastocytosis in bone marrow: clinicopathologic features and an algorithmic approach to diagnosis.
Reichard KK; Chen D; Pardanani A; McClure RF; Howard MT; Kurtin PJ; Wood AJ; Ketterling RP; King RL; He R; Morice WG; Hanson CA
Am J Clin Pathol; 2015 Sep; 144(3):493-502. PubMed ID: 26276780
[TBL] [Abstract][Full Text] [Related]
20. FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells.
Crescenzi B; Chase A; Starza RL; Beacci D; Rosti V; Gallì A; Specchia G; Martelli MF; Vandenberghe P; Cools J; Jones AV; Cross NC; Marynen P; Mecucci C
Leukemia; 2007 Mar; 21(3):397-402. PubMed ID: 17215855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
